Toggle Main Menu Toggle Search

Open Access padlockePrints

Considerations on blood glucose management in type 2 diabetes mellitus

Lookup NU author(s): Emeritus Professor Philip Home


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


In recent years the benefits of more intensive management in preventing or delaying the development and progression of diabetic complications have been well documented. What is not as well documented is how to motivate the person with diabetes to manage the condition, how to set, assess and quantify glucose goals, and the glucose variables that should be routinely measured. This review discusses the importance of setting targets and communicating them in a way that the patient understands. When aiming for a glycaemia target, balance is required (1) between achieving reduction of complications and causing an increased degree of hypoglycaemia, and (2) between what is achievable and what degree of benefit is gained. Target values given in guidelines should be adapted by the clinician to take into account the patient's susceptibility to hypoglycaemia, stage and type of complications, age and life expectancy, co-morbidity, social environment, understanding of the steps required and level of commitment to the treatment. Several suggestions are given regarding possible improvements and amendments to existing guidelines for diabetes management in treating to glucose goal. For example, attention should be drawn to the need to individualise goals and to consider education, long-term support, patient needs and treatment outcome when formulating diabetes management plans. The relative properties of the different glucose variables - fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated haemoglobin A1c (HbA1c), and glycated protein - in terms of their convenience of measurement, usefulness and relevance to the physician and patient are also evaluated. When prioritising the variables to be measured it is suggested that where feasible, HbA1c should be the standard measurement by which to gauge risk and treatment efficacy. Serial measurements should be made and, where possible, the use of blood glucose meters encouraged, in order to obtain a blood glucose profile for the patient. Copyright © 2002 John Wiley & Sons, Ltd.

Publication metadata

Author(s): Home P; Chacra A; Chan J; Emslie-Smith A; Sorensen L; Van Crombrugge P

Publication type: Review

Publication status: Published

Journal: Diabetes/Metabolism Research and Reviews

Year: 2002

Volume: 18

Issue: 4

Pages: 273-285

ISSN (print): 1520-7552

ISSN (electronic): 1520-7560


DOI: 10.1002/dmrr.312

PubMed id: 12203943